The week of September 7 to 11, 2026, concluded with a mixed bag of results for the five health and pharmaceutical stocks listed on the Casablanca stock exchange. With three stocks experiencing gains and two suffering losses, the performance disparities underscore the absence of a homogeneous "health sector" within the Casablanca stock market. Instead, it reveals five distinct industrial trajectories that characterize this segment.
When compared to the previous Friday's closing on September 4, the difference between the best and worst performing stocks reached an impressive 9.38 percentage points. Sothema emerged as the top performer with a remarkable gain of 7.35%, while T2S Group Holding recorded the steepest decline, falling by 2.03%. In between, Akdital saw a modest increase of 1.30%, Promopharm edged up by 0.15%, and Vicenne experienced a decrease of 0.87%.
As of September 11, the consolidated market capitalization of the health sector stood at 40.29 billion dirhams, reflecting an increase of over a billion dirhams over the week. Notably, two stocks alone accounted for more than three-quarters of this total value: Akdital at 16.50 billion dirhams and Sothema at 13.98 billion dirhams. A closer examination reveals three distinct dynamics within the sector.
Sothema Sets the Pace
Sothema, a laboratory based in Bouskoura, delivered the strongest weekly performance among health stocks. Starting at 340 dirhams at the close on September 4, it ended the week at 365 dirhams, an increase of 7.35% over five sessions. The stock reached a weekly high of 365 dirhams on Friday's close, with a low of 350 dirhams recorded during Monday's session.
The intra-week trajectory unfolded in two phases: a significant jump on Tuesday, September 8, where the stock gained 3.17% to close at 361.20 dirhams, followed by another surge on Thursday, September 10, reaching 364.90 dirhams after a brief consolidation on Wednesday. Friday's session helped stabilize this upward movement.
Trading volume for the week remained modest at 1.45 million dirhams across 4,003 shares, with a capital rotation of just 0.01% during the period. This low turnover indicates the stock's limited liquidity, suggesting that the rise was driven by targeted buying pressure rather than broad market flows.
Akdital Maintains Its Lead
As the leading player in the sector by market capitalization, the private hospital operator Akdital demonstrated a robust week, albeit without dramatic fluctuations. The AKT stock closed on Friday at 1,165 dirhams, up from 1,150 dirhams on September 4, marking a slight increase of 1.30%. The company's market capitalization reached 16.50 billion dirhams.
During the week, trading volume amounted to 34.92 million dirhams across 30,129 shares, making it the highest volume in the sector. However, the capital rotation remained limited at 0.21%, indicating a tightly held stock. The peak price for the week was recorded at 1,167 dirhams on Friday, while the lowest point was 1,140 dirhams on Monday, reflecting a contained price fluctuation of 2.37%.
Trading activity accelerated during the last two sessions, with over 23 million dirhams traded on Thursday and Friday, compared to less than 12 million during the first three sessions, showcasing a shift in trading dynamics without unsettling the stock price.
Vicenne and T2S: The Outliers
The recent market entry did not shield the two youngest stocks in the sector from unfavorable performance. T2S Group Holding experienced a decline of 2.03% over the five sessions, dropping from 231.50 dirhams on September 4 to 226.80 dirhams by Friday. The trading volume reached 26.35 million dirhams for 114,800 shares, showcasing the best rotation in the sector at 0.53% of the capital.
Vicenne's profile was more mixed. The stock closed at 340 dirhams on Friday, down 0.87% from September 4, yet exhibited notable intra-week volatility: peaking at 353.90 dirhams and dipping to 338 dirhams, resulting in an amplitude of 4.70%. The session on Wednesday, September 9, accounted for the bulk of the activity, with trades totaling 14.90 million dirhams, closely followed by Tuesday's 11.60 million dirhams. This spike in trading deserves attention.
Finally, Promopharm maintained its usual pace as a nearly illiquid stock: just two trading sessions out of five, with a weekly volume of 111,579 dirhams across 81 shares, and a nominal gain of 0.15% to 1,379 dirhams.
The consolidated analysis reveals a clear dichotomy within the sector. The three most liquid stocks, Akdital, Vicenne, and T2S, accounted for 98.3% of the volumes traded during the week, with respective shares of 36.6%, 34.1%, and 27.6%. In contrast, Sothema and Promopharm combined for less than 2% of total trading flows, despite their combined market weight exceeding 15 billion dirhams.
This disparity between market capitalization and actual liquidity highlights a structural divide within the sector. On one side are two historic pharmaceutical companies with limited float and trading activity, whose stock prices reflect long-term positioning. On the other, three younger or more dynamic entities, including two medtech firms and a hospital operator, which attract the attention of managers and capture the bulk of trading flows.
This week, the performance hierarchy did not align with trading volume. Sothema, nearly absent from transactions, recorded the highest increase, while T2S, buoyed by trading volumes, faced the steepest decline. A useful reminder: at the Casablanca stock exchange, volume does not equate to performance.
As reported by telquel.ma.
